• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyloxycarbonyls

Benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate (CAS No. 370881-43-9): A Comprehensive Overview

Benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate (CAS No. 370881-43-9) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of bicyclic amines and is characterized by its bicyclo[3.2.0]heptane core, which imparts it with a high degree of conformational rigidity and specific stereochemical configurations.

The bicyclo[3.2.0]heptane scaffold is a privileged structure in drug discovery, known for its ability to modulate various biological targets, including receptors, enzymes, and ion channels. The presence of the benzyl group in the molecule further enhances its pharmacological profile by influencing its lipophilicity and metabolic stability. These properties make benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate an attractive candidate for the development of novel therapeutics.

Recent studies have explored the potential of benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate in various therapeutic areas. One notable application is in the treatment of neurological disorders, such as Alzheimer's disease and Parkinson's disease. Research has shown that this compound can effectively cross the blood-brain barrier and exhibit neuroprotective effects by modulating key signaling pathways involved in neuronal survival and function.

In addition to its neuroprotective properties, benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate has also been investigated for its potential as an anti-inflammatory agent. In vitro and in vivo studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines and reduce oxidative stress, making it a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.

The structural rigidity and specific stereochemistry of benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate also contribute to its favorable pharmacokinetic properties. The compound exhibits good oral bioavailability and a long half-life, which are crucial factors for effective drug delivery and sustained therapeutic effects. These characteristics have been validated through extensive preclinical studies and are currently being further explored in clinical trials.

One of the key challenges in the development of benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate is optimizing its synthetic route to ensure high yield and purity while minimizing environmental impact. Recent advancements in green chemistry have led to the development of more sustainable synthesis methods that reduce waste generation and energy consumption. These methods not only align with environmental sustainability goals but also enhance the economic viability of large-scale production.

In conclusion, benzyl (1S,5S)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate (CAS No. 370881-43-9) represents a promising molecule with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and favorable pharmacological properties make it an attractive candidate for further investigation and development into novel therapeutics for various diseases.

• 122536-73-6(benzyl (3R)-3-aminopyrrolidine-1-carboxylate)
• 927389-50-2(Benzyl 3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidine-1-carboxylate)
• 1017789-40-0(1-Cbz-3-amino-4-hydroxymethylpyrrolidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)